Purpose To compare the long-term outcomes of accelerated corneal collagen crosslinking (CXL) to conventional CXL for progressive keratoconus.
Introduction
Keratoconus is an ectatic corneal disorder characterised by progressive thinning and conical protrusion that results in irregular astigmatism and decreased vision. 1, 2 Collagen crosslinking (CXL) has emerged as the standard of care for progressive keratoconus over the last decade. Several studies have evaluated the clinical efficacy of the procedure and reported favourable outcomes in terms of stable corneal curvatures and improved visual acuity. [3] [4] [5] CXL involves administration of riboflavin (vitamin B2) in conjunction with ultraviolet A (UVA, 365 nm) causing a photochemical process that leads to photopolymerisation of collagen molecules with resultant increased corneal biomechanical rigidity and biochemical resistance. 6, 7 The original CXL procedure (epithelium-off Dresden protocol) includes a 30 min instillation of drops (0.1% riboflavin in 20% dextran) followed by 30 min of UVA illumination at 3 mW/cm 2 for 30 min (5.4 J/cm 2 dose). 3, 4 The requirement for epithelial removal and the lengthy duration of procedure (60 min) encouraged several variations of the standard protocol, including transepithelial CXL via iontophoresis (10 min of riboflavin exposure followed by 30 min of UVA treatment).
Experimental and clinical studies have demonstrated that iontophoresis-assisted transepithelial CXL is an effective method for riboflavin impregnation of the corneal stroma and for stabilising keratoconus progression. 8, 9 Comparative studies however report better results with conventional CXL. 10 More recently, accelerated CXL procedures have been developed as an alternative technique, where higher energy settings have been used. These techniques use an irradiance of upto 30 mW/cm 2 . This permits a shortening of the overall exposure time from 30 min to as little as 3-10 min while maintaining the total radiant exposure (5.4J/cm 2 ). [11] [12] [13] [14] [15] [16] [17] [18] [19] Accelerated CXL may be performed in either a pulsed or a continuous manner. Pulsing the UV light during CXL hypothetically restarts the photodynamic reaction thus achieving an additional oxygen concentration allowing more singlet oxygen release for CXL. 20 Lately, iontophoresis-assisted accelerated CXL with epithelial debridement (total treatment time of 15 min) has also been described with favourable preliminary results. 21 Currently, most clinical studies report that accelerated CXL has an effect equivalent to or better than conventional CXL. [11] [12] [13] 18, 22 However, a few recent studies demonstrated a significantly greater treatment effect with conventional CXL. 14, 15 The biomechanical effect of CXL has been demonstrated to be oxygendependent and therefore it is possible that increasing fluence to accelerate photopolymerisation may not allow adequate time for oxygen to diffuse and participate in the reaction. 23, 24 A recent review article compared accelerated and conventional CXL protocols and concluded that although the safety and effectiveness of the procedures with regard to stability seem to be equivalent, the ancillary measures of efficacy, including demarcation line depth and laboratory measurements do not always confirm equivalence of both protocols. 25 Most studies on accelerated CXL have reported short-term results. Very few reports exist in literature with 12 months' or greater follow-up 14, 22 particularly in comparison to conventional CXL. 15, 18, 22 Hence, there is a paucity of clinical data on the longitudinal outcome of accelerated CXL. The present study aims to evaluate the long-term efficacy of accelerated CXL in comparison to conventional CXL for progressive keratoconus.
Materials and methods
This study was conducted at the Envision Eye Centre, Sydney. The study protocol was approved by the human ethics committee and adhered to the principles proposed by the declaration of Helsinki.
Participants
This was a retrospective, non-randomised comparative study of progressive keratoconic eyes that underwent accelerated CXL (21 eyes) and were compared to a historic cohort of conventional CXL-treated eyes (21 eyes) performed by the same surgeon (JJM).
The inclusion criteria for either conventional or accelerated CXL were eyes with early to moderate progressive keratoconus with a corneal thickness of at least 400 μm. Progressive keratoconus was defined as eyes that exhibited an increase in keratometry in the steep meridian (K2) of 1.00 D in 1 year, deterioration in visual acuity, and the need for new contact lens fitting more than once in 2 years. 5 Exclusion criteria were advanced keratoconus with stromal scarring, corneal hydrops, herpetic keratitis, autoimmune and other systemic diseases, pregnancy, and breast feeding. Eyes with minimum 12 months' follow-up after CXL were included and all eyes underwent corneal topography using a scheimpflug camera (Pentacam HR, Oculus Inc., Wetzlar, Germany). We have not considered one eye for each patient as keratoconus is an asymmetric disease.
Surgical technique
All eyes underwent epithelium-off procedures performed by the same surgeon (JJM). Accelerated CXL was done using the Innocross system; 30 min riboflavin (Innocross R, IROC Innocross AG, Zug, Switzerland) presoak and 10 min of 370 nm, 9 mW/cm 2 UVA light exposure.
Similarly, conventional CXL was performed using the Innocross system; 30 min riboflavin (Innocross R) presoak and 30 min of 370 nm, 3 mW/cm 2 UVA light exposure.
Measurements
Pre-and post-procedure changes in keratometry readings (flat meridian: K1; steep meridian: K2), central corneal thickness (CCT), best spectacle-corrected visual acuity (BSCVA), and manifest refraction spherical equivalent (MRSE) were compared between both treatment groups. Each group was subdivided into two groups based on keratometry readings, those with pre-CXL K2 greater than (advanced cases) or less than 50 D (less-advanced cases) and results were compared. The Pentacam HR is a high-resolution Scheimpflug camera that takes multiple slit images of the anterior segment in o2 s while rotating 180°around the eye. It uses a measurement wavelength of 475 nm (blue lightemitting diode) and 25 000 measurement points are obtained. Measurements were taken with subjects in a sitting position looking at the fixation target according to the manufacturer's instructions. Only scans that the Pentacam's 'Quality specification' function determined as 'OK' were included for analysis.
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Statistics
Statistical analysis was performed using the Graphpad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA). Measurements obtained from both devices were described as mean ± SD. The comparison between baseline parameters between groups was performed using the unpaired t-test and the Fisher's exact test. The differences between pre-and post-CXL values were examined using a paired t-test. For all analysis, a P-value of o0.05 was considered statistically significant.
Results
A total of 42 eyes were included in this study (21 eyes after accelerated CXL vs 21 eyes after conventional CXL). Both treatment groups were followed up for comparable periods of time. The accelerated CXL group had a followup of 20.5 ± 5.5 months (range 12 − 30 months) and the conventional CXL group was followed up for 20.2 ± 5.6 months (range 12 − 28 months).
Baseline characteristics
A comparison of baseline demographics, including age, gender, CCT, K1, K2, MRSE, and BSCVA was performed and no significant differences were noted between both groups ( Table 1) . The rates of atopy were 42.9% and 57.1% in the accelerated and conventional CXL groups respectively. Baseline keratoconus cone morphology was also studied. In the accelerated CXL group, the distribution was noted to be nipple cones (28.6%) and oval cones (71.4%), whereas in the conventional CXL group, it was nipple cones (42.9%) and oval cones (57.1%).
Corneal curvature change
In the accelerated CXL group, K2 (keratometry reading at the steep meridian) reduced by mean 1.11 ± 2.01 D (P = 0.02), whereas in the conventional group, K2 reduced by mean 0.61 ± 1.18 D (P = 0.04) at final follow-up. Although both groups exhibited statistically significant reductions in keratometry readings, no significant differences were noted between them (P = 0.36; Table 2 ). The trend of change in K2 values over time in both conventional and accelerated CXL groups is shown in Figure 1 . Corneal topography showing regression in keratometry values at 12 months after accelerated CXL is shown in Figure 2 .
Both accelerated and conventional CXL groups were divided into advanced (pre-CXL K2 more than 50 D) and less-advanced (pre-CXL K2 o50 D) subgroups. There were 8 advanced and 13 less-advanced eyes in the accelerated CXL group as compared to 6 advanced and 15 less-advanced eyes in the conventional group. No significant differences in topographic response (post-CXL K2 minus pre-CXL K2) were noted between the advanced and less-advanced subgroups of both accelerated (P = 0.50) and conventional (P = 0.37) CXL groups. Because of the small subgroup sample size, these numbers are not adequately powered to detect significant differences.
During follow-up, keratometric progression was noted in 4 of 21 accelerated CXL-treated eyes (range of change in K2 values was − 0.4 to − 1.1 D) and in 6 of 21 conventional CXLtreated eyes (range of change in K2 values was − 0.1 to − 1 D).
Visual acuity change
Improvements in BSCVA and MRSE were noted in both groups, however were not statistically significant. At final follow-up, 63.2% of accelerated CXL-treated eyes gained one or more lines of BSCVA in comparison to 47.4% of conventional CXL-treated eyes (Figure 3 ).
Corneal thickness change
The post-procedure change in CCT did not differ significantly between both groups (P = 0.14). ) and conventional methods of corneal CXL and at 6 months' follow-up, demonstrated an equivalent effect. Mean decrease in maximum keratometry values were not statistically significantly different between both groups. The mean changes in corneal biomechanical parameters, including corneal hysteresis and corneal resistance factor were also similar in both groups. 11 Kanellopoulos performed a contralateral comparative study of high-fluence accelerated CXL (UVA irradiance 7 mW/cm 2 ) vs conventional CXL and reported a significant decrease in the steep keratometry with associated reduction in MRSE and improvement in BSCVA in both treatment groups at 6 months post treatment. 13 The long-term efficacy of accelerated CXL (UVA irradiance 9 mW/cm 2 , 10 min) was assessed by Elbaz et al 12 in a cohort of 16 eyes at 6 and 12 months after the Eye procedure with improvements in uncorrected visual acuity and stable keratometry values noted. Likewise, at mean follow-up of 21.7 months, improvement in keratometry and stabilisation of corrected distance visual acuity were noted after accelerated CXL (18 mW/cm) in progressive keratoconic eyes. 16 Very few studies have compared the long-term outcomes of conventional and accelerated CXL. Recently, Shetty et al 18 studied the efficacy of different protocols of CXL in treating progressive keratoconus and reported comparable visual, refractive, and tomographic improvements after conventional CXL and accelerated CXL with irradiations of 9 and 18 mW/cm 2 at 12 months. Another study by Cummings et al 22 noted significantly greater corneal flattening after accelerated CXL with respect to conventional CXL at 12 months. In contrast, the corneal-flattening effect of conventional CXL (18 mW/ cm 2 ) was greater than that of accelerated CXL in a current study by Chow et al. 15 The present study has a long follow-up for both accelerated (UVA irradiance 9 mW/cm 2 ) and conventional CXL groups, being followed up for mean 20 (range 12-30) months post treatment. Sixteen of 21 eyes (76%) in the accelerated CXL group and 17 of 21 eyes (81%) in the conventional CXL had follow-up 412 months. To the best of our knowledge, this study has the longest follow-up period for a comparative study between outcomes of both treatment groups. Statistically significant reductions in steep keratometry readings were noted after both accelerated (51.19 ± 6.01 to 49.95 ± 4.90 D) and conventional (48.50 ± 2.92 to 47.89 ± 3.62 D) CXL with no difference between both groups.
Improvements in BSCVA and MRSE were observed after both procedures, however was not statistically significant. The changes in K2 and MRSE parameters were greater with the accelerated CXL group as compared to the conventional CXL group, although not statistically significant. These changes likely contributed to greater number of patients in the accelerated CXL group gaining a line of BSCVA compared to the conventional group. In summary, the findings of this study indicate that accelerated and conventional CXL appear to be equally efficient in managing progressive keratoconus and these results are consistent with previous similar longitudinal studies. 16, 18, 22 A current prospective, interventional study compared the functional results in two groups of patients undergoing epithelium-off pulsed accelerated CXL (pl-ACXL) at 30 mW/cm 2 UVA exposure for 8 min (1 s on/ 1 s off) vs continuous light accelerated CXL (cl-ACXL) at 30 mW/cm2 for 4 min. 28 Results at 12 months' follow-up demonstrated keratoconus stability in both groups. However, deeper stromal penetration and better functional outcomes were noted in the pl-ACXL group indicating that pulsed light optimised intraoperative oxygen availability thereby improving postoperative results. The topographic simulated mean K-value demonstrated a statistically significant reduction by − 1.2 D (P = 0.049) after pl-ACXL, whereas an insignificant reduction by − 0.13 D was noted after cl-ACXL (P = 0.088). In comparison, in the present study, K2 reduced by mean 1.11 D (P = 0.02) in the accelerated CXL group and by mean 0.61 D in the conventional group (P = 0.04) at final follow-up of mean 20 months. These results are however not directly comparable as higher energy doses were used in the pl-ACXL vs cl-ACXL study ( Findings of a recent study by Chan et al 29 suggest that accelerated CXL causes greater topographic flattening and is more effective in advanced keratoconus cases compared to less-advanced cases. The present study did not find any difference in topographic response between different grades of keratoconus for either conventional or accelerated CXL treatments. However, these results were limited by a small subgroup sample size.
One limitation of the present study is that the change in corneal biomechanical parameters and endothelial count was not assessed and compared between treatment groups. One other interesting aspect might have been detailed corneal imaging to compare structural changes post accelerated and conventional CXL procedures. Toubol et al 30 performed in vivo corneal confocal microscopy following both procedures and reported significant differences in corneal healing with accelerated CXL producing a greater impact than conventional CXL on the anterior cornea. One of the drawbacks of conventional CXL is the prolonged exposure time (30 min). Accelerated CXL, being a shorter procedure with equivalent results, could offer a benefit to the patients. A larger study with emphasis on biomechanical and structural changes following both treatment protocols is recommended to further validate the results of this study.
Summary
What was known before K Accelerated corneal crosslinking is effective in stabilising progressive keratoconus.
